Currently, there is insufficient robust evidence to conclude that neoadjuvant therapy significantly impacts survival in patients with Luminal A and Luminal B subtypes of breast cancer, unlike its effect on HER2-positive and triple-negative neoplasms29. This evidence concerns the gene ERBB2 and breast carcinoma.